Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Gowrisankar Rajam is active.

Publication


Featured researches published by Gowrisankar Rajam.


Critical Reviews in Microbiology | 2008

Pneumococcal Surface Adhesin A (PsaA): A Review

Gowrisankar Rajam; Julie M. Anderton; George M. Carlone; Jacquelyn S. Sampson; Edwin W. Ades

Pneumococcal surface adhesin A (PsaA) is a surface-exposed common 37-kilodalton multi-functional lipoprotein detected on all known serotypes of Streptococcus pneumoniae. This lipoprotein belongs to the ABC-type transport protein complex that transports Mn2+; it is also an adhesin that plays a major role in pneumococcal attachment to the host cell and virulence. PsaA is immunogenic and natural nasopharyngeal colonization of pneumococci elicits an increase in antibody towards PsaA. Hence, PsaA is being actively evaluated as a component of a vaccine in formulations composed of pneumococcal common proteins. PsaA has been expressed as an E. coli recombinant protein, purified, and evaluated in a phase one clinical trial. This article reviews PsaA, its structure and role in pneumococcal virulence, immunogenicity, and potential to reduce nasopharyngeal colonization (a major prerequisite for pneumococcal pathogenesis) as a component of a common pneumococcal protein vaccine.


The Journal of Infectious Diseases | 2010

Revaccination with a 23-Valent Pneumococcal Polysaccharide Vaccine Induces Elevated and Persistent Functional Antibody Responses in Adults Aged ⩾65 Years

Susan B. Manoff; Charles Liss; Michael J. Caulfield; Rocio D. Marchese; Jeffrey L. Silber; John W. Boslego; Sandra Romero-Steiner; Gowrisankar Rajam; Nina E. Glass; Cynthia G. Whitney; George M. Carlone

BACKGROUND Older adults are at high risk of developing invasive pneumococcal disease, but the optimal timing and number of vaccine doses needed to prevent disease among this group are unknown. We compared revaccination with 23-valent pneumococcal polysaccharide vaccine (PN23) with primary vaccination for eliciting initial and persistent functional antibody responses. METHODS Subjects aged > or = 65 years were enrolled. Functional (opsonic) and total immunoglobulin (Ig) G antibody levels were measured following either PN23 primary vaccination (n = 60) or revaccination 3-5 years after receiving a first PN23 vaccination (n = 60). Antibody against vaccine serotypes 4, 14, and 23F was measured at prevaccination (day 0), 30 days after vaccination, and 5 years after vaccination. RESULTS By day 30, both primary vaccination and revaccination induced significant increases in opsonic and IgG antibody levels. Day 30 levels following revaccination were slightly lower but not significantly different than those after primary vaccination. Year 5 levels were similar in both groups and remained significantly higher than prevaccination levels for primary vaccination subjects. There was good agreement between postvaccination opsonic and IgG antibody levels. CONCLUSIONS Revaccination of older adults with PN23 was comparable to primary vaccination for inducing elevated and persistent functional and IgG antibody responses.


Critical Reviews in Microbiology | 2008

RETRACTED: Pneumococcal Surface Adhesin A (PsaA): A Review

Gowrisankar Rajam; Julie M. Anderton; George M. Carlone; Jacquelyn S. Sampson; Edwin W. Ades

RETRACTED: Correct version published at http://informahealthcare.com/doi/abs/10.1080/10408410802275352


Clinical and Vaccine Immunology | 2007

Functional Antibodies to the O-Acetylated Pneumococcal Serotype 15B Capsular Polysaccharide Have Low Cross-Reactivities with Serotype 15C

Gowrisankar Rajam; George M. Carlone; Sandra Romero-Steiner

ABSTRACT The 23-valent pneumococcal polysaccharide (Ps) vaccine offer protection against vaccine serotypes, but its cross-protection against vaccine-related serotypes is variable. We have demonstrated that the functional antibodies to serotype 15B are specific to the O-acetylated 15B-Ps and that they have low cross-reactivity with serotype 15C. Demonstration of functionally cross-reactive antibodies to vaccine-related serotypes is important for surveillance and vaccine development.


The Journal of Infectious Diseases | 2012

P4-Mediated Antibody Therapy in an Acute Model of Invasive Pneumococcal Disease

Mathieu Bangert; Laura Bricio-Moreno; Suzanna Gore; Gowrisankar Rajam; Edwin W. Ades; Stephen B. Gordon; Aras Kadioglu

New treatments against severe bacterial infections are needed because the response to antibiotic treatment is slow in acute settings and is becoming less effective owing to the emergence of antibiotic-resistant pathogens. P4-mediated antibody therapy offers a unique treatment strategy that combines exogenous immunoglobulin with the immunoactivating peptide P4. In an acute model of pneumococcal disease, mice were infected with Streptococcus pneumoniae and treated intravenously or intranasally with P4 and intravenous immunoglobulin (IVIG). Survival of P4-IVIG-treated mice increased from 0% to 60% among those that received intravenous treatment and from 0% to 100% among those that received intranasal treatment. Importantly, intranasal administration of P4 at an early stage of infection prevented the onset of bacteremia and sepsis. Increased survival was associated with reduced bacterial burden in affected tissues and with recruitment and activation of professional phagocytes, as manifested by increased expression of Fc-γ receptors. In vitro studies involving P4-stimulated alveolar, peritoneal, and J774.2 murine macrophages showed an increased ability of these immune cells to phagocytose pneumococci independent of capsule. The use of adjunct antibody therapies to treat infectious diseases shows promise.


Antimicrobial Agents and Chemotherapy | 2011

Immunotherapy with a Combination of Intravenous Immune Globulin and P4 Peptide Rescues Mice from Postinfluenza Pneumococcal Pneumonia

Jenni N. Weeks; Kelli L. Boyd; Gowrisankar Rajam; Edwin W. Ades; Jonathan A. McCullers

ABSTRACT Alternate therapies are needed for treatment of secondary bacterial pneumonia following influenza. The immunomodulatory peptide P4 has shown promise in mouse models of primary pneumococcal infection. Mice infected with influenza virus and then challenged with Streptococcus pneumoniae were treated with a combination of P4 peptide and intravenous immune globulin. Survival was improved from 20% to 80% in treated mice relative to controls. Clinical cure correlated with increased clearance of bacteria and decreased lung consolidation. Greater trafficking of professional phagocytic cells to the site of pneumococcal infection coupled with enhanced opsonophagocytosis as manifest by decreased surface display of Fcγ receptors (FcγR) on neutrophils and macrophages were associated with P4 peptide treatment. This suggests that the mechanism of action for improved clearance of bacteria engendered by P4 is through improved uptake by phagocytes mediated by IgG Fc-Fcγ receptor interactions following antibody-mediated opsonophagocytosis of bacteria. Antibody-based therapies, when coupled with immune modulators, such as P4 peptide, may be an effective tool together with antibiotics in our armamentarium against severe pneumonia.


The Journal of Infectious Diseases | 2017

Meningococcal Carriage Following a Vaccination Campaign With MenB-4C and MenB-FHbp in Response to a University Serogroup B Meningococcal Disease Outbreak—Oregon, 2015–2016

Lucy A McNamara; Jennifer Dolan Thomas; Jessica R. MacNeil; How Yi Chang; Michael Day; Emily Fisher; Stacey W. Martin; Tasha Poissant; Susanna Schmink; Evelene Steward-Clark; Laurel T. Jenkins; Xin Wang; Anna M. Acosta; Kristina M. Angelo; Amy Blain; Pam Cassiday; Shankar Changayil; Elizabeth Chandler Church; Kasey Diebold; Sinmisola Ewumi; Amanda Faulkner; Helen Fisun; Holly Haberman; Brian H. Harcourt; Sterling Haring; Lauren Hughes; Sandeep Joseph; Nivritti Kumaran; Adria Lee; Tanya Lennon

Background Limited data exist on the impact of the serogroup B meningococcal (MenB) vaccines MenB-FHbp and MenB-4C on meningococcal carriage and herd protection. We therefore assessed meningococcal carriage following a MenB vaccination campaign in response to a university serogroup B meningococcal disease outbreak in 2015. Methods A convenience sample of students recommended for vaccination provided oropharyngeal swab specimens and completed questionnaires during 4 carriage surveys over 11 months. Isolates were tested by real-time polymerase chain reaction analysis, slide agglutination, and whole-genome sequencing. Vaccination history was verified via university records and the state immunization registry. Results A total of 4225 oropharyngeal swab specimens from 3802 unique participants were analyzed. Total meningococcal and genotypically serogroup B carriage prevalence among sampled students were stable, at 11%-17% and 1.2%-2.4% during each round, respectively; no participants carried the outbreak strain. Neither 1-3 doses of MenB-FHbp nor 1-2 doses of MenB-4C was associated with decreased total or serogroup B carriage prevalence. Conclusions While few participants completed the full MenB vaccination series, limiting analytic power, these data suggest that MenB-FHbp and MenB-4C do not have a large, rapid impact on meningococcal carriage and are unlikely to provide herd protection in the context of an outbreak response.


Vaccine | 2010

Concomitant administration of recombinant PsaA and PCV7 reduces Streptococcus pneumoniae serotype 19A colonization in a murine model.

Melissa Whaley; Jacquelyn S. Sampson; Scott E. Johnson; Gowrisankar Rajam; Annie Stinson-Parks; Patricia Holder; Sandra Romero-Steiner; George M. Carlone; Edwin W. Ades

A murine colonization model was used to determine the effect of co-administering 7-valent polysaccharide-protein conjugate vaccine and pneumococcal surface adhesin A. Mice were challenged intranasally with either PCV7 serotypes, 4 or 14, or a non-PCV7 serotype, 19A. Post-challenge samples were evaluated for IgG antibody levels, opsonophagocytic activity, and nasopharyngeal colonization. No interference was observed between immune responses from the concomitant and individual immunizations. Concomitant immunizations reduced carriage for tested serotypes; largest reduction was observed for 19A. From these mouse studies, co-administering pneumococcal antigens appear to expand coverage and reduce colonization against a non-PCV7 serotype without inhibiting immunogenicity to other serotypes.


The Journal of Infectious Diseases | 2009

A 28-aa Pneumococcal Surface Adhesin A–Derived Peptide, P4, Augments Passive Immunotherapy and Rescues Mice from Fatal Pneumococcal Infection

Gowrisankar Rajam; Julie M. Skinner; Nikkol Melnick; Joseph E. Martinez; George M. Carlone; Jacquelyn S. Sampson; Edwin W. Ades

BACKGROUND P4, a 28-aa peptide derived from pneumococcal surface adhesin A, is a multilineage cell activator in vitro. We hypothesized that P4-mediated activation of phagocytic cells could rapidly and substantially increase opsonophagocytosis of bacteria, which could be translated in vivo to reduced mouse morbidity from fatal pneumococcal infection. METHODS Reference in vitro opsonophagocytic killing and uptake assays were used with suitable effector cells and pathogen-specific antibodies. P4 peptide solution was added at the preopsonization stage. ND4-SW mice were infected intranasally with Streptococcus pneumoniae serotype 3 (WU2). At 72 and 96 h, infected mice received intraperitoneal or intravenous injection of gamma globulin, followed by an injection of P4. RESULTS P4 treatment enhanced in vitro opsonophagocytosis of bacterial pathogens by many fold, and this effect was dependent on complement, P4, and antibody concentrations. Treatment of highly virulent WU2-infected mice with the combination of P4 and serotype-specific antiserum resulted in 100% remission of bacteremia and rescued 80% of the animals (P < .05). CONCLUSION P4 peptide in combination with pathogen-specific antibodies and complement enhances specific opsonophagocytosis and rescues mice from life-threatening pneumococcal infection. P4 peptide provides a fresh direction for therapeutic intervention through augmented passive immunotherapy.


Clinical and Vaccine Immunology | 2005

Fluorescent Multivalent Opsonophagocytic Assay for Measurement of Functional Antibodies to Streptococcus pneumoniae

Kathryn T. Bieging; Gowrisankar Rajam; Patricia Holder; Ross Udoff; George M. Carlone; Sandra Romero-Steiner

ABSTRACT We developed fluorescent mono- and multivalent opsonophagocytic assays (fOPA and fmOPA, respectively) specific for seven Streptococcus pneumoniae serotypes (4, 6B, 9V, 14, 18C, 19F, and 23F). Bacterial survival was quantitated with alamar blue, a fluorescent metabolic indicator. Both fOPA and fmOPA allow for determination of viability endpoints for up to seven serotypes with high levels of agreement to the reference method. The fmOPA eliminates colony counting, reduces serum volume, and produces results in 1 day.

Collaboration


Dive into the Gowrisankar Rajam's collaboration.

Top Co-Authors

Avatar

George M. Carlone

Centers for Disease Control and Prevention

View shared research outputs
Top Co-Authors

Avatar

Edwin W. Ades

Centers for Disease Control and Prevention

View shared research outputs
Top Co-Authors

Avatar

Jacquelyn S. Sampson

Centers for Disease Control and Prevention

View shared research outputs
Top Co-Authors

Avatar

Sandra Romero-Steiner

Centers for Disease Control and Prevention

View shared research outputs
Top Co-Authors

Avatar

Nikkol Melnick

Centers for Disease Control and Prevention

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Mathieu Bangert

Liverpool School of Tropical Medicine

View shared research outputs
Top Co-Authors

Avatar

Stephen B. Gordon

Liverpool School of Tropical Medicine

View shared research outputs
Top Co-Authors

Avatar

Ellie Kim

Centers for Disease Control and Prevention

View shared research outputs
Top Co-Authors

Avatar

Julie M. Anderton

Centers for Disease Control and Prevention

View shared research outputs
Researchain Logo
Decentralizing Knowledge